Navigation Links
Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients
Date:8/1/2009

SAN FRANCISCO (August 1, 2009)Previously untreated non-small cell lung cancer (NSCLC) patients over the age of 70 respond well to a combination of bevacizumab and erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.

"Based on our initial data, the combination appears to be well tolerated and efficacious, though we'll have to wait and see the final results," says Hossein Borghaei, D.O., medical oncologist at Fox Chase, who led the trial.

Elderly patients are often excluded from clinical trials because researchers fear they will have trouble tolerating standard chemotherapy regimens. That leaves open the question of how best to treat these individuals who account for more than half of all NSCLC in the United States.

With that challenge in mind, Borghaei and colleagues designed a trial testing a combination of two molecularly targeted agents in patients 70 years or older. The team reasoned that a combination lacking standard cytotoxic agents may be better tolerated by these patients, potentially without comprising efficacy. "We looked for a regimen that had few side effects, would involve only targeted agents, and had a bit of a track record. This combination was a natural fit," Borghaei says. Several small phase II trials in younger NSCLC patients demonstrated that the combination had anti-tumor activity and a relatively favorable toxicity profile.

Thus far 21 elderly NSCLC patients have enrolled in the Fox Chase trial and 14 are evaluable for response. The median age of the 14 evaluable patients is 78, with a range of 71 to 84 years. Four patients have had partial responses with demonstrable tumor shrinkage and three patients had stable disease by RECIST criteria.

The combination appears safe and well tolerated in this patient population with the most commonly encountered toxicities of clinical relevance being high blood pre
'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
2. Northstar Healthcare Announces Option to Purchase a 60% Interest in The Palladium for Surgery - Dallas
3. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
4. Consumer Group: Hillary Clintons Mandatory Health Insurance Purchase Plan is an Act of War on the Middle Class Family That Cant Afford $12k Policy
5. Kensey Nash Announces $25 Million Stock Repurchase Program
6. Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance
7. Flextronics Announces Redemption and Change of Control Repurchase Offer for Solectron 8.00% Senior Subordinated Notes and Planned Change of Control Repurchase Offer for Solectrons 0.50% Senior Convertible Notes
8. First Nationwide Class Action Filed on Behalf of Consumers Who Purchased Topps E. Coli Contaminated Ground Beef
9. Hospital Corporation of America Purchases Seventh CyberKnife(R) System
10. Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics
11. Governor Schwarzeneggers Mandatory Purchase of Private Health Insurance Doesnt Add Up for the Middle-Class, Says FTCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... online in The Gerontologist reports ... associated with a decrease in anxiety about death and ... over their lives. In particular, listening to gospel music ... and an increase in sense of control. , These ... men, and individuals of both low- and high-socioeconomic status. ...
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2
... ROCKVILLE, Md., March 5 Americans and nonprofit organizations ... of these circumstances, The Larry King Cardiac Foundation (LKCF), ... for individuals with no health insurance, has announced that ... 2009.In lieu of its annual black tie gala held ...
... happens may lead to ways around it, researchers say, ... standard treatment for brain cancer, may boost the aggressiveness ... a new study suggests. , The research team, from ... identified cells in brain tumors called gliomas that have ...
... response to a recent report by the National Council ... U.S. population is exposed to seven times more radiation ... Americans to consider the proven benefits of such imaging. ... technologists support the use of diagnostic imaging when deemed ...
... WASHINGTON, March 5 Stephen J. Ubl, president and CEO ... the Medical Device Safety Act to be introduced today in Congress. If ... , Chill innovation and ... Dramatically alter the regulatory environment for certain medical devices, ...
... March 5 Stephen J. Ubl, president ... released the following statement today regarding the re-introduction of ... not in any way improve patient safety. It will, ... a chilling effect on medical innovation, create more lawsuits ...
... Dialysis Corporation of America (Nasdaq: DCAI ) announced its financial ... , , ... dialysis center acquired December 31, 2008. , ... $23.7 million compared to $20.0 million for the same period last year, ...
Cached Medicine News:Health News:The Larry King Cardiac Foundation Brings its Annual Gala to Homes Across the Nation 2Health News:The Larry King Cardiac Foundation Brings its Annual Gala to Homes Across the Nation 3Health News:Brain Tumor Drug May Help Spur Cancer's Return 2Health News:Brain Tumor Drug May Help Spur Cancer's Return 3Health News:Medical imaging benefits far outweigh radiation risks 2Health News:AdvaMed Response to the Medical Device Safety Act 2Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 2Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 3Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 4Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 5Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 6Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 7Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 8
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Novavax, Inc. (Nasdaq: NVAX ), a clinical-stage vaccine ... Novavax, will be presenting at the ROTH 23rd Annual OC ... local time at The Ritz Carlton, Laguna Niguel, CA.  A ... via the Company website at www.novavax.com under Investors/Events, ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... the extracellular matrix for the endocrinology, ... financial results for the fourth quarter and year ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) "I am energized and ...
Cached Medicine Technology:Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 2Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 4Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 5Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 6
Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
Bipolar forceps...
... the pathologist to visualize the presence of Human ... a choice of sample types: tissue, monolayer-based preparations, ... proprietary probe formulations. The Family 16 probe cocktail ... 31, 33, 35, 39, 51, 52, 56, 58, ...
... Common primary human fungal pathogens ... spp., opportunistic fungal pathogens, including ... cerevisiae, Acremonium, Coccidioides immitis, Histoplasma ... and Pneumocystis carinii. The (1-3)--D-glucan ...
Medicine Products: